ISTA Pharmaceuticals is proud to announce the approval of BROMDAY by the U.S. FDA. BROMDAY is the first and only once daily ophthalmic NSAID for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. BROMDAY competes in the $335 million U.S. ophthalmic NSAID market.
BROMDAY is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. One drop of BROMDAY ophthalmic solution should be applied to the affected eye(s) once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.
WARNINGS AND PRECAUTIONS
• Sulfite Allergic Reactions
• Slow or Delayed Healing
• Potential for cross-sensitivity
• Increase bleeding of ocular tissues
• Corneal effects including keratitis
• Contact Lens Wear
The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging).
Rx only, please see full prescribing information